Ad-hoc | 18 June 2001 08:36

EVOTEC BioSystems AG english

Ad hoc announcement processed and transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Evotec OAI and MelTec form Joint Venture and Enter into a Drug Discovery Service Collaboration Hamburg, Germany/ Abingdon, UK/ Magdeburg, Germany – Evotec OAI (EVOTEC BioSystems AG, Neuer Markt: EVT) and MelTec GmbH, a pioneer in topological proteomics, announced today that they have entered into a collaboration. The agreement involves the formation of a new company as well as the development and marketing of a novel joint service package, synergistically combining both companies’ core technologies. The new company will be jointly founded by Evotec OAI and MelTec, with both companies sharing 50% of the equity each before financing. It will specialise in the discovery, development and marketing of selective, highly effective and well tolerated drugs, for selected autoimmune diseases and cancer types with unmet medical needs. The integration of Evotec OAI’s drug discovery platform and MelTec’s WCPF (Whole Cell Protein Fingerprinting) proteomics technology will significantly enhance the efficiency of the drug discovery and development process. MelTec’s WCPF approach is based on the fact that healthy tissue is encoded by correctly expressed proteins: each protein being expressed at the right time, at the right concentration, at the right subcellular location. In contrast, pathophysiological tissue can be recognised because some proteins do not display the correct spatial arrangement. Targets can thus be validated for their pathophysiological relevance and the response to drug action in model systems tested. Forming a joint venture with MelTec in selected indication areas is further evidence of the successful implementation of Evotec OAI’s business strategy, i.e. to open up potential new fields of expansion by getting access to equity stakes in relevant and promising new ventures which secure financing with institutional venture capital investors or in partnerships with the pharmaceutical industry. Under the Service Agreement Evotec OAI and MelTec will jointly offer their expertise in drug discovery to third parties. The combination of the complementary technologies will substantially shorten the overall time frame of the drug development process. At the same time it will maximise the probability of clinical success. In addition, the companies will jointly develop novel ADMET assays examining side effect profiles and toxicity of drug candidates in model systems and human tissue. MelTec’s innovative proteomics technology will allow Evotec OAI to provide its customers access to a very sophisticated solution to prioritise hits and lead structures for drug candidates. Under the terms of this agreement, Evotec OAI has committed to an upfront payment of Euro 5 million and downstream royalties to MelTec on Evotec OAI service offerings. EVOTEC BioSystems AG Anne Hennecke, Investor Relations Phone: +49-40-56081286 Fax: +49-40-56081333 E-mail: anne.hennecke@evotecoai.com end of ad hoc announcement (c) DGAP 18.06.2001 ——————————————————————————– WKN: 566480; Index: NEMAX-50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 180836 Jun 01